Can a drug save Insulin-Making cells in kids with New-Onset diabetes?
NCT ID NCT03782636
First seen Nov 01, 2025 · Last updated Jun 24, 2026 · Updated 27 times
Summary
This phase 2 trial is testing whether aldesleukin, a drug that helps regulate the immune system, can preserve insulin production in children and young adults (ages 6-18) recently diagnosed with type 1 diabetes. Participants receive either aldesleukin or a placebo for 6 months, and researchers measure changes in C-peptide levels (a marker of insulin production). The goal is to see if the drug can slow the loss of natural insulin-making ability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE1 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Addenbrooke's Hospital
Cambridge, United Kingdom
-
Bristol Royal Hospital for Children
Bristol, United Kingdom
-
Nottingham Children's Hospital
Nottingham, United Kingdom
-
Oxford Children's Hospital
Oxford, Oxfordshire, OX3 9DU, United Kingdom
-
The Great North Children's Hospital
Newcastle upon Tyne, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aldesleukin (a lab-made version of interleukin-2, a protein that helps regulate the immune system)
What this could lead to
If it works, this could point toward a way to preserve natural insulin production in people newly diagnosed with type 1 diabetes, potentially reducing their long-term reliance on insulin injections.
What could go wrong
This is a small, early-phase trial with only 41 participants, so results may not apply to everyone. Aldesleukin can cause flu-like symptoms and skin reactions, and it is unclear if it will meaningfully preserve insulin production over time.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.